Solventum Corporation $SOLV is Terril Brothers Inc.’s 7th Largest Position

Terril Brothers Inc. lifted its position in Solventum Corporation (NYSE:SOLV) by 2.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 271,851 shares of the company’s stock after purchasing an additional 6,850 shares during the period. Solventum accounts for about 5.6% of Terril Brothers Inc.’s investment portfolio, making the stock its 7th biggest position. Terril Brothers Inc. owned approximately 0.16% of Solventum worth $21,541,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Hilltop National Bank boosted its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum in the third quarter valued at approximately $25,000. JNBA Financial Advisors boosted its holdings in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in shares of Solventum in the second quarter valued at approximately $28,000. Finally, City State Bank boosted its holdings in shares of Solventum by 166.7% in the fourth quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after purchasing an additional 240 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SOLV shares. Wedbush started coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target for the company. Rothschild & Co Redburn assumed coverage on Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. KeyCorp upped their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, BTIG Research restated a “buy” rating and set a $89.00 target price on shares of Solventum in a report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Stock Down 0.8%

Solventum stock opened at $76.23 on Wednesday. The business has a fifty day moving average of $69.09 and a two-hundred day moving average of $74.94. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm has a market cap of $13.20 billion, a P/E ratio of 9.34, a P/E/G ratio of 1.19 and a beta of 0.59. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s revenue was down 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts forecast that Solventum Corporation will post 6.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.24% of the stock is currently owned by corporate insiders.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.